How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,019 results for

"covid 19" OR "novel coronavirus"

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis

COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis Evidence summary Published: 21 May 2020 www.nice.org.uk/guidance/es26 pathways Key messages Key messages The content of this evidence review was up-to-date on 13 May 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE (...) activation syndrome [MAS]), malignancy (especially haematological malignancy) or, most often, infection (when it may be indistinguishable from sepsis). Viral infections are the most common cause of secondary sHLH (Carter et al. 2019). © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 5The COVID-19 virus (SARS-CoV-2) can produce a profound cytokine response in the host, with raised levels of many inflammatory mediators

2020 National Institute for Health and Clinical Excellence - Advice

62. COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19

of more severe COVID-19 (The Novel Coronavirus Pneumonia Emergency Response Epidemiology T eam 2020). COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES25) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 4Factors for decision making Factors for decision making Effectiveness and safety Effectiveness and safety The searches (...) COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 COVID-19 rapid evidence summary: Long-term use of non- steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 Evidence summary Published: 21 May 2020 www.nice.org.uk/guidance/es25 pathways Key messages Key messages The content of this evidence review was up-to-date on 20 April 2020. See summaries of product characteristics (SPCs

2020 National Institute for Health and Clinical Excellence - Advice

63. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19

COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 COVID-19 rapid evidence summary: acute use of non- steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 Evidence summary Published: 14 April 2020 www.nice.org.uk/guidance/es23 pathways Key messages Key messages The content of this evidence review was up-to-date on 24 March 2020. See summaries of product characteristics (SPCs), British (...) national formulary (BNF) or the MHRA or NICE websites for up-to-date information. In March 2020, the French Health Ministry issued advice to avoid using non-steroidal anti- inflammatory drugs (NSAIDs) to treat symptoms of COVID-19 because these medicines might aggravate the infection. In response to these concerns, the MHRA issued a Central alerting system (CAS) alert in which the NHS England Medical Director, Professor Stephen Powis, advised using paracetamol in preference to ibuprofen in people

2020 National Institute for Health and Clinical Excellence - Advice

64. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. Full Text available with Trip Pro

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. To study the clinical characteristics of patients in Zhejiang province, China, infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease 2019 (covid-2019).Retrospective case series.Seven hospitals in Zhejiang province, China.62 patients admitted to hospital with laboratory confirmed SARS

2020 BMJ

65. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Full Text available with Trip Pro

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients.All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients

2020 Lancet

66. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Full Text available with Trip Pro

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. In December, 2019, a pneumonia associated with the 2019 novel coronavirus (2019-nCoV) emerged in Wuhan, China. We aimed to further clarify the epidemiological and clinical characteristics of 2019-nCoV pneumonia.In this retrospective, single-centre study, we included all confirmed cases of 2019-nCoV in Wuhan Jinyintan Hospital from Jan 1 to Jan 20, 2020. Cases were

2020 Lancet

67. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Full Text available with Trip Pro

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. In late December, 2019, patients presenting with viral pneumonia due to an unidentified microbial agent were reported in Wuhan, China. A novel coronavirus was subsequently identified as the causative pathogen, provisionally named 2019 novel coronavirus (2019-nCoV). As of Jan 26, 2020, more than 2000 cases of 2019-nCoV infection have been confirmed, most of which involved

2020 Lancet

68. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Full Text available with Trip Pro

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. An ongoing outbreak of pneumonia associated with a novel coronavirus was reported in Wuhan city, Hubei province, China. Affected patients were geographically linked with a local wet market as a potential source. No data on person-to-person or nosocomial transmission have been published to date.In this study, we report the epidemiological, clinical (...) travelled to Wuhan, five were identified as infected with the novel coronavirus. Additionally, one family member, who did not travel to Wuhan, became infected with the virus after several days of contact with four of the family members. None of the family members had contacts with Wuhan markets or animals, although two had visited a Wuhan hospital. Five family members (aged 36-66 years) presented with fever, upper or lower respiratory tract symptoms, or diarrhoea, or a combination of these 3-6 days

2020 Lancet

69. A Novel Coronavirus from Patients with Pneumonia in China, 2019. Full Text available with Trip Pro

A Novel Coronavirus from Patients with Pneumonia in China, 2019. In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily

2020 NEJM

70. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. Full Text available with Trip Pro

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The initial cases of novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) occurred in Wuhan, Hubei Province, China, in December 2019 and January 2020. We analyzed data on the first 425 confirmed cases in Wuhan to determine the epidemiologic characteristics of NCIP.We collected information on demographic characteristics, exposure history, and illness timelines of laboratory-confirmed cases of NCIP that had

2020 NEJM

71. COVID-19: guidance for stepdown of infection control precautions within hospitals and discharging COVID-19 patients from hospital to home settings

COVID-19: guidance for stepdown of infection control precautions within hospitals and discharging COVID-19 patients from hospital to home settings COVID-19: guidance for stepdown of infection control precautions within hospitals and discharging COVID-19 patients from hospital to home settings - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve (...) accepted all cookies. You can at any time. Hide Search Stay at home Only go outside for food, health reasons or work (but only if you cannot work from home) If you go out, stay 2 metres (6ft) away from other people at all times Wash your hands as soon as you get home Do not meet others, even friends or family. You can spread the virus even if you don’t have symptoms. Guidance COVID-19: guidance for stepdown of infection control precautions within hospitals and discharging COVID-19 patients from

2020 Public Health England

72. COVID-19 Aviation Health Safety Protocol: Guidance for the management of airline passengers in relation to the COVID-19 pandemic

COVID-19 Aviation Health Safety Protocol: Guidance for the management of airline passengers in relation to the COVID-19 pandemic COVID-19 Aviation Health Safety Protocol Operational Guidelines for the management of air passengers and aviation personnel in relation to the COVID-19 pandemic Issue no: 01 Issue date: 20/05/2020 COVID-19 Aviation Health Safety Protocol Guidance for the management of airline passengers in relation to the COVID-19 pandemic Issue no: 01 Issue date: 20/05/2020 European (...) Union Aviation Safety Agency (EASA) Konrad-Adenauer-Ufer 3, 50679 Cologne, Germany Phone: +49 221 89990 000 Web: www.easa.europa.eu/coronavirus-covid-19 European Centre for Disease Prevention and Control (ECDC) Gustav III:s boulevard 40, 169 73 Solna, Sweden Phone +46 (0)8 58 60 10 00 www.ecdc.europa.eu Page 2 of 28 Table of Contents 1 Background 3 2 General considerations 4 Principles based on best available evidence 4 3. Passenger management 6 3.1 At all times 6 3.2. Before arriving at the airport

2020 European Centre for Disease Prevention and Control - Technical Guidance

73. Supporting person-centred care in COVID-19 situations: Sharing compassionate practice under COVID-19 conditions

Supporting person-centred care in COVID-19 situations: Sharing compassionate practice under COVID-19 conditions Person-centred communication in COVID-19 | People Led Care | ihub - Supporting person-centred care in COVID-19 situations Search People-Led Care Person-Centred Health and Care / / / / Supporting person-centred care in COVID-19 situations Connecting colleagues to support wellbeing Keeping morale high and prioritising wellbeing is hard for staff at stressful, busy times. Maintaining (...) therapeutic relationships How to overcome the communication barrier between COVID-19 patients and care staff wearing PPE. Here are some care improvement ideas. Caring for children during COVID-19 It can be daunting for a child to be in hospital. The backdrop of COVID-19 and PPE adds extra anxiety. Here are some child-friendly ways to explain. Caring for those with additional needs When COVID-19 patients have trouble seeing or hearing, or have special needs, other ways to communicate compassionately may

2020 Covid-19 Ad hoc papers

74. Covid-19: Guidance for preventing and controlling COVID-19 outbreaks in New Zealand aged residential care

Covid-19: Guidance for preventing and controlling COVID-19 outbreaks in New Zealand aged residential care Health Quality & Safety Commission | Guidance for preventing and controlling COVID-19 outbreaks in New Zealand aged residential care Rārangi matua Main Menu Mortality review committees are statutory committees that review particular deaths, or the deaths of particular people, in order to learn how to best prevent these deaths. › › › Aged Residential Care Navigation Menu Projects Guidance (...) for preventing and controlling COVID-19 outbreaks in New Zealand aged residential care 3 Apr 2020 | This guidance document and supporting resources provide practical assistance to aged residential care facilities in response to the global COVID-19 pandemic. Please note: These documents are being updated regularly and links may change. Instead of downloading the documents, please use and share the link to this page and return here to get the most recent versions. We welcome all feedback on the guide

2020 Covid-19 Ad hoc guidelines

75. Covid-19: Guidance for managing staff and residents with COVID-19 infection in aged residential care facilities

on use of nebulisers for residents with COVID-19 as this is an aerosol generating procedure. • When a facility is notified of a probable or confirmed case, the facility should work with their local public health unit, follow the Ministry of Health’s online Updated advice for health professionals: novel coronavirus (COVID-19) to start identifying and isolating all other residents and staff who may be close or casual contacts, and convene their outbreak management team. • If a resident tests positive (...) : novel coronavirus (COVID-19) about release from isolation of confirmed or probable COVID-19 cases. Infection prevention and control Hand hygiene is one key essential action that prevents transmission of infection. In addition to hand hygiene measures, all staff must adhere to standard precautions and droplet and contact precautions as necessary when caring for residents with suspected or confirmed COVID-19 and residents who have respiratory and influenza-like symptoms. Advice on PPE for droplet

2020 Covid-19 Ad hoc guidelines

76. COVID-19 rapid evidence summary: vitamin D for COVID-19

coronavirus infection that causes COVID-19. This evidence summary sets out the best available evidence on vitamin D for preventing or treating COVID-19, or for the susceptibility to COVID-19 based on vitamin D status. Treating or preventing acute respiratory tract infections more generally was out of scope. The Scientific Advisory Committee on Nutrition (SACN) has published a report on vitamin D and acute respiratory tract © NICE 2020. All rights reserved. Subject to Notice of rights (https (...) COVID-19 rapid evidence summary: vitamin D for COVID-19 COVID-19 rapid evidence summary: vitamin D for COVID-19 Evidence summary Published: 29 June 2020 www.nice.org.uk/guidance/es28 pathways Key messages Key messages The content of this evidence summary was up-to-date on 18 June 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA, NHS or NICE websites for up-to-date information. Vitamin D is important for bone and muscle health. It has also been

2020 NICE COVID-19 rapid evidence summary

77. Perioperative Management of Patients Infected with the Novel Coronavirus: Recommendation from the Joint Task Force of the Chinese Society of Anesthesiology and the Chinese Association of Anesthesiologists. Full Text available with Trip Pro

Perioperative Management of Patients Infected with the Novel Coronavirus: Recommendation from the Joint Task Force of the Chinese Society of Anesthesiology and the Chinese Association of Anesthesiologists. The outbreak of the new Coronavirus disease, COVID-19, has been involved in 77,262 cases in China as well as in 27 other countries as of February 24, 2020. Because the virus is novel to human beings, and there is no vaccine yet available, every individual is susceptible and can become

2020 Anesthesiology

78. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Full Text available with Trip Pro

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. In the recent outbreak of novel coronavirus infection in Wuhan, China, significantly abnormal coagulation parameters in severe novel coronavirus pneumonia (NCP) cases were a concern.To describe the coagulation feature of patients with NCP.Conventional coagulation results and outcomes of 183 consecutive patients with confirmed NCP in Tongji hospital were retrospectively analyzed.The

2020 Journal of Thrombosis and Haemostasis

79. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Full Text available with Trip Pro

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Three months ago, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan, China, and spread rapidly around the world. Severe novel coronavirus pneumonia (NCP) patients have abnormal blood coagulation function, but their venous thromboembolism (VTE) prevalence is still rarely mentioned.To determine the incidence of VTE in patients with severe NCP.In this study, 81 severe NCP

2020 Journal of Thrombosis and Haemostasis

80. Clinical Analysis of 25 Novel Coronavirus Infections in Children. (Abstract)

Clinical Analysis of 25 Novel Coronavirus Infections in Children. To describe the characteristics of clinical manifestations of children with 2019 novel coronavirus (2019-nCoV) infection in Chongqing.All 25 children with laboratory-confirmed 2019-nCoV infection by real-time reverse transcription-PCR (RNA-PCR) were admitted from the 4 designated treatment hospitals of 2019-nCoV in Chongqing from January 19 to March 12, 2020. Clinical data and epidemiological history of these patients were

2020 Pediatric Infectious Dsease Journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>